Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

The Original Article was published on 27 August 2019

Correction to: Leukemia

https://doi.org/10.1038/s41375-019-0552-3

Following the publication of this article, the authors noted minor errors in Supplementary Fig. 5. The correct version of this figure is included below along with the accompanying figure legend.

Supplementary Fig. 5: LY3214996 potently inhibits proliferation of human primary patient AML cells in a concentration-dependent manner.
figure1

(A, B) Proliferation studies; 3-day LY3214996 treatment (A) or 6-day treatment (B) of primary AML patient samples. (C, D) Proliferation studies; 3-day LY3214996 treatment (C) or 6-day treatment (D) of normal PBMCs versus human AML cells. (E) LY3214996 treatment of AML patient sample 14 for 3 days. (F-G) Proliferation studies; 3-day LY3214996 or AZD6244 treatment of AML patient samples 12 (F) and 13 (G). Patient and primagraft information for all samples shown in this manuscript is provided in Supplementary Tables 1 and 2.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Ellen Weisberg or James D. Griffin.

Additional information

The original article can be found online at https://doi.org/10.1038/s41375-019-0552-3.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weisberg, E., Meng, C., Case, A. et al. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 2543 (2020). https://doi.org/10.1038/s41375-020-0782-4

Download citation

Search